JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age

By Ming Xu, T. Tchkonia, H. Ding, M. Ogrodnik, Ellen R Lubbers, T. Pirtskhalava, T. White, Kurt O. Johnson, Michael B. Stout, V. Mezera and 4 more. Proceedings of the National Academy of Sciences of the United States of America, 2015

792 citations recorded by the source corpus.

Subfields: Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/de9857e51cdf87687b54009b3f695ce70a6d0d6b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Kirkland
2. T. Tchkonia
3. M. Demaria
4. Jesús Gil
5. Yi Zhu
6. J. Campisi
7. Y. Fouad
8. C. Aanei

In Physiology

1. J. Kirkland
2. T. Tchkonia
3. Jesús Gil
4. M. Demaria
5. J. Campisi
6. Jodie Birch
7. Yi Zhu
8. A. Alimonti

Citations in the corpus

• Aging and aging-related diseases: from molecular mechanisms to interventions and treatments (2022, background): “Senomorphic drugs, such as JAK inhibitors and mTOR inhibitors, do not kill senescent cells but inhibit the secretion of SASP components.(615) The JAK inhibitor ruxolitinib reduces the size of the secretome derived from senescent cells.”
• Senescence and the SASP: many therapeutic avenues (2020, background): “For instance, the JAK1/2 inhibitor ruxolitinib reduces the proinflammatory SASP, in vitro and in vivo and enhances insulin sensitivity, limits osteoporosis and reduces frailty in ageing mice (Xu et al. 2015a,b; Farr et al. 2017).”
• Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (2017, result): “Interference with JAK-STAT signaling is known not to affect the viability of senescent cells (Xu et al., 2015), and we have previously observed similar effects for NFkB and p53 inhibition (Freund et al.”
• Fisetin is a senotherapeutic that extends health and lifespan (2018, background): “Reducing senescent cell burden can lead to reduced inflammation, decreased macromolecular dysfunction, and enhanced function of stem/progenitor cells [1,3,19].”
• Cellular Senescence: Aging, Cancer, and Injury. (2019, background): “Ruxolitinib is a Janus kinase inhibitor previously discovered to inhibit production of multiple SASP factors (350).”